- DeepMind’s CEO, Demis Hassabis, predicts that advancements in artificial intelligence could significantly reduce the drug discovery timeline from several years to just months.
- This breakthrough aims to address the high failure rates that currently plague the pharmaceutical industry.
- The implications of such a shift could lead to faster development of new medicines, potentially transforming healthcare outcomes.
AI poised to revolutionize drug discovery, says DeepMind CEO
DeepMind's CEO, Demis Hassabis, predicts that advancements in artificial intelligence could significantly reduce the drug discovery timeline from several years to just months. This breakthrough aims to address the high failure rates that currently plague the pharmaceutical industry. The implications of such a shift could lead to faster development of new medicines, potentially transforming healthcare outcomes.